Moderna press release straight out of “1984”, “TeenCOVE Study of its COVID-19 Vaccine in Adolescents Meets Primary Endpoint”, Kids need protection from big Pharma not Covid-19

Moderna press release straight out of “1984”, “TeenCOVE Study of its COVID-19 Vaccine in Adolescents Meets Primary Endpoint”, Kids need protection from big Pharma not Covid-19

“Why are we vaccinating healthy adults when 81 percent of Covid-19 cases are mild and there is  a 99 percent survival rate. Why are we testing vaccines on children who are minimally impacted by the disease?”…Citizen Wells

“it is universally known that children virtually never die from COVID-19 and given that children have a very strong immune system, they are more likely than adults to have an over-reaction to the shot.”…Dr. Steven Roth

“By looking at the difference between adults and children in these quarantines, deCODE found that children play a minor role in transmission.”…Iceland Covid transmission study

From Moderna May 25, 2021.

“Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the Phase 2/3 study of its COVID-19 vaccine (mRNA-1273) in adolescents has met its primary immunogenicity endpoint, successfully bridging immune responses to the adult vaccination. In the study, no cases of COVID-19 were observed in participants who had received two doses of the Moderna COVID-19 vaccine using the primary definition. In addition, a vaccine efficacy of 93% in seronegative participants was observed starting 14 days after the first dose using the secondary CDC case definition of COVID-19, which tested for milder disease. This study, known as the TeenCOVE study, enrolled more than 3,700 participants ages 12 to less than 18 years in the U.S. The Company plans to submit these data to regulators globally in early June.

“We are encouraged that mRNA-1273 was highly effective at preventing COVID-19 in adolescents. It is particularly exciting to see that the Moderna COVID-19 vaccine can prevent SARS-CoV-2 infection,” said Stéphane Bancel, Chief Executive Officer of Moderna. “We will submit these results to the U.S. FDA and regulators globally in early June and request authorization. We remain committed to doing our part to help end the COVID-19 pandemic.”

In this Phase 2/3 study, 3,732 adolescent participants ages 12 to less than 18 years were enrolled and randomized 2:1 to two 100 µg doses of mRNA-1273 or placebo. The primary endpoint of non-inferior immunogenicity versus the Phase 3 adult study comparator group was met. After two doses, no cases of COVID-19 were observed in the vaccine group using the case definition from the adult Phase 3 COVE study, compared to 4 cases in the placebo group, resulting in a vaccine efficacy of 100% starting 14 days after the second dose. Because the incidence rate of COVID-19 is lower in adolescents, a secondary case definition based on the CDC definition of COVID-19 was also evaluated to include cases presenting with milder symptoms. Using the CDC definition, which requires only one COVID-19 symptom and a nasopharyngeal (NP) swab or saliva sample positive for SARS-CoV-2 by RT-PCR, a vaccine efficacy of 93% after the first dose was observed.

mRNA-1273 was generally well tolerated with a safety and tolerability profile generally consistent with the Phase 3 COVE study in adults. No significant safety concerns have been identified to date. The majority of adverse events were mild or moderate in severity. The most common solicited local adverse event was injection site pain. The most common solicited systemic adverse events after the second dose of mRNA-1273 were headache, fatigue, myalgia and chills.

Safety data continues to accrue, and the study continues to be monitored by an independent safety monitoring committee. All participants will be monitored for 12 months after their second injection to assess long-term protection and safety. Consequently, these data are subject to change based on ongoing data collection. The Company plans to submit data from the TeenCOVE study to a peer-reviewed publication.”

https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-teencove-study-its-covid-19-vaccine

Straight out of “1984”.

First of all, kids do not need protection from Covid-19, they need protection from big Pharma and the government.

Dr. Mike Yeadon, former vice president of Pfizer:

“Because COVID vaccines use experimental technology that may pose serious side effects such as blood clots, Yeadon said, “we should absolutely not be offering them to young, healthy people who are not at risk from the virus.””

“I have two healthy adult girls, 25 and 29 years-old, and I would be really upset if they ended up being coerced into taking these products because they’re healthy and young, and there are not any measurable risks from COVID-19.”

Secondly they tout a 93 percent efficacy rate.

The placebo group in a FDA report from May 10, 2021 had a better rate than that.

“The FDA study states that 16 out of 978 placebo recipients got Covid. That is 1.6 percent.

The death rate for Covid in this age group is nearly statistically zero.

The known risks are frightening. The unknown perhaps more frightening. (see below)”

Once again, this study proves nothing about protecting kids.

Immediate adverse events were noted but the longer term implications are the “devil we don’t know.”

More here:

https://citizenwells.com/

http://citizenwells.net/

https://parler.com/profile/Citizenwells/posts